Inhibrx Biosciences (INBX) Set to Release Quarterly Earnings on Friday

Key Points

• Inhibrx Biosciences is scheduled to report Q3 2026 results after market close Friday, November 13. Analysts expect a loss of $2.45 per share and revenue of $1.90 million.
• The company’s previous quarter loss of $2.34 per share missed the $2.28 consensus estimate. Shares were down 7.5% and opened at $80.28, below their 50-day moving average of $99.62.
• Analyst views are mixed, though MarketBeat’s average rating is “Moderate Buy” with a $197.50 price target. Insiders have bought 62,540 shares worth about $6.35 million over the past 90 days.

Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) is expected to be issuing its Q3 2026 results after the market closes on Friday, November 13th. Analysts expect Inhibrx Biosciences to post earnings of ($2.45) per share and revenue of $1.90 million for the quarter. Individuals can find conference call details on the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($2.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.28) by ($0.06). On average, analysts expect Inhibrx Biosciences to post ($9.91) EPS for the current fiscal year and ($9.34) EPS for the next fiscal year.

Inhibrx Biosciences Stock Down 7.5%

Shares of NASDAQ INBX opened at $80.28 on Friday. Inhibrx Biosciences has a one year low of $57.30 and a one year high of $155.29. The business's fifty day moving average price is $99.62 and its 200-day moving average price is $91.74.

Wall Street Analyst Weigh In

INBX has been the subject of several recent research reports. Citigroup reissued a "market perform" rating on shares of Inhibrx Biosciences in a report on Friday, September 18th. HC Wainwright started coverage on Inhibrx Biosciences in a research note on Monday, August 24th. They issued a "buy" rating and a $245.00 price objective on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Inhibrx Biosciences in a report on Friday, September 11th. Finally, Wall Street Zen lowered shares of Inhibrx Biosciences from a "hold" rating to a "strong sell" rating in a research report on Monday, August 17th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Inhibrx Biosciences currently has an average rating of "Moderate Buy" and an average price target of $197.50.

Insider Buying and Selling at Inhibrx Biosciences

In related news, Director Jon Kayyem bought 5,000 shares of the company's stock in a transaction on Tuesday, September 8th. The shares were purchased at an average price of $113.52 per share, for a total transaction of $567,600.00. Following the completion of the transaction, the director directly owned 424,360 shares in the company, valued at approximately $48,173,347.20. The trade was a 1.19% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Mark Lappe purchased 25,000 shares of the business's stock in a transaction dated Tuesday, September 8th. The stock was bought at an average cost of $105.82 per share, with a total value of $2,645,500.00. Following the completion of the acquisition, the chief executive officer directly owned 730,548 shares of the company's stock, valued at approximately $77,306,589.36. This trade represents a 3.54% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have acquired 62,540 shares of company stock valued at $6,347,507 and have sold 1,500 shares valued at $168,590. Corporate insiders own 18.26% of the company's stock.

Inhibrx Biosciences Company Profile

Inhibrx Biosciences, Inc is a biotechnology company focused on developing biologic medicines for serious and rare diseases. The company uses its proprietary protein-engineering and antibody-development platforms to create therapies designed to address conditions with limited treatment options.

Its lead investigational program was INBRX-101, an engineered recombinant protein developed for alpha-1 antitrypsin deficiency-associated lung disease. The company also advanced other potential treatments, including INBRX-109, an investigational therapy studied in certain solid tumors, and additional biologic candidates targeting oncology and other serious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.